Itolizumab

伊立珠单抗

Report date: 2026/05/13 20:02:10
First In Class

Base Information

Drug NameItolizumab
Drug Alias NameAlzumab-LAlzumabT-1-hTEQ-001T-1-h +[8] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionAnti-CD6
TargetsT-cell differentiation antigen CD6
Therapy Area/IndicationsPlaque psoriasisCoronavirus Disease 2019 (COVID-19)Graft vs Host Disease +[9] 
Global Approved IndicationsPlaque psoriasis
Approved Indications in ChinaN/A
Original Approved Country/TerritoryIndia
Original Approved Date2013/01/01
Country/TerritoryBelgiumCanadaUnited States +[16] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesCenter Of Molecular Immunology
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesBiotech Pharmaceutical Co LtdEquillium Aus Pty LtdEquillium Inc +[6] 
Inactive CompaniesN/A
Active IndicationsPlaque psoriasisLupus Erythematosus, CutaneousLupus Nephritis +[6] 
Inactive IndicationsCoronavirus Disease 2019 (COVID-19)Graft vs Host DiseasePsoriasis

Other Information

ATC CodeL01XC
Related LinksWikipedia